Humoral and Cell‐Mediated Immune Responses to an Early 2‐Dose Measles Vaccination Regimen in the United States

Abstract

Measles vaccination elicits T cell responses in infants as young as 6 months old, which may prime the humoral response to the second dose. Initiating measles vaccination as an early 2-dose regimen results in an immunologic response that is likely to have clinical benefits in developed and developing countries.